Archive · 24 Dec 2025
Zydus Partners with Bioeq for US Marketing of NUFYMCO
Zydus Lifesciences, a big Indian medicine company, has teamed up with Bioeq, a Swiss company, to sell a medicine called NUFYMCO in the United States.
NUFYMCO is a copy of another medicine called Lucentis, which helps people with eye problems like wet age-related macular degeneration and diabetic macular edema.
The US government's health department, the FDA, has approved NUFYMCO.
Zydus will sell the medicine in the US, while Bioeq will make it.
This teamwork will help more people get the medicine they need.
Zydus's stock price went up a little bit on the day they announced this partnership.
Zydus Lifesciences partners with Bioeq AG to market NUFYMCO in the US.
NUFYMCO is a biosimilar to Lucentis, used for treating wet age-related macular degeneration and diabetic macular edema.
FDA approved NUFYMCO's Biologics License Application on December 18, 2025.
Zydus will commercialize the product in the US, while Bioeq handles development, manufacturing, and supply.
Zydus's share price increased by 1.23% on December 23, 2023, following the announcement.
- Who
- Zydus Lifesciences Limited and Bioeq AG
- What
- Strategic partnership for marketing NUFYMCO in the US
- When
- December 23, 2023 (announcement), December 18, 2025 (FDA approval)
- Where
- United States
- Why
- To expand access to affordable ophthalmology care and broaden treatment options
- Companies Involved
- Zydus Lifesciences Limited, Bioeq AG
- Product
- NUFYMCO (biosimilar to Lucentis)
- Approval Date
- December 18, 2025
- Regulatory Body
- US Food and Drug Administration (FDA)
- Conditions Treated
- Neovascular (wet) age-related macular degeneration (AMD), Diabetic macular edema (DME)
- Zydus Share Price
- ₹929.45 (up 1.23%)